FDA Policy and the Future of Peptide Access

The Regulatory Framework

Peptide access in the United States is governed by an overlapping set of federal and state laws, regulatory agencies, and evolving policy interpretations. Understanding this framework is essential not just for legal compliance, but because regulatory shifts can change peptide access rapidly — a peptide that is widely available through compounding pharmacies today could face new restrictions tomorrow based on a single FDA policy decision.

DSHEA and Why Peptides Are Not Supplements

The Dietary Supplement Health and Education Act of 1994 (DSHEA) created the regulatory framework for dietary supplements. Under DSHEA, dietary supplements do not require FDA pre-market approval and are regulated much less stringently than drugs. The act defines a dietary supplement as a product intended to supplement the diet that contains a "dietary ingredient" — vitamins, minerals, herbs, amino acids, or concentrates, metabolites, or extracts thereof.

Could peptides qualify as dietary supplements? Some argue that because peptides are chains of amino acids, and amino acids are explicitly included in DSHEA's definition, certain peptides could be marketed as supplements. However, the FDA has consistently taken the position that therapeutic peptides — those intended to treat, diagnose, cure, or prevent disease — are drugs, not supplements, regardless of their amino acid composition. The distinction hinges on intended use: an amino acid powder sold as a nutritional supplement is one thing; a synthetic peptide sequence designed to activate a specific receptor is something else entirely.

This distinction matters because it determines which regulatory pathway applies. If a peptide is a drug, it requires either FDA approval or legal compounding under 503A/503B. If it were a supplement, it could be sold over the counter without a prescription. The FDA's consistent classification of therapeutic peptides as drugs means the higher standard applies.

The NDA Pathway and Its Economics

The New Drug Application (NDA) process is the gold standard for bringing a drug to market in the US. It requires the sponsor to submit comprehensive preclinical data, clinical trial data from Phase I (safety), Phase II (dosing and preliminary efficacy), and Phase III (large-scale efficacy and safety) trials, along with manufacturing specifications and proposed labeling.

The economics of the NDA process are formidable. Estimates for the total cost of developing a new drug and bringing it through FDA approval range from $1 billion to over $2.5 billion, and the timeline is typically 10 to 15 years. These costs are recoverable when the drug achieves patent-protected market exclusivity — which is why pharmaceutical companies invest in the process.

For many peptides used in compounding, the NDA path is economically non-viable. Some are natural sequences that cannot be patented effectively. Others serve relatively small patient populations that cannot generate sufficient revenue to justify the investment. This economic reality is why the compounding pathway is so important — it provides legal access to medically useful peptides that no company has brought through FDA approval.

503B Oversight: Expanding and Evolving

The 503B outsourcing facility framework, created by the Drug Quality and Security Act (DQSA) of 2013, was born out of tragedy — the 2012 New England Compounding Center contamination disaster that killed 64 people. The DQSA created a voluntary registration pathway for compounding facilities willing to submit to FDA oversight and cGMP requirements in exchange for the ability to compound without patient-specific prescriptions.

Since 2013, FDA oversight of 503B facilities has expanded considerably. The agency conducts regular inspections, issues warning letters for violations, and has shut down facilities that failed to meet standards. The FDA publishes a list of registered 503B facilities, along with inspection results and any enforcement actions taken.

One of the most significant and contentious aspects of 503B regulation is the FDA's "essentially a copy" doctrine. The FDA has asserted that 503B facilities cannot compound drugs that are "essentially a copy" of a commercially available FDA-approved drug unless that drug is on the FDA's shortage list. This policy has been at the center of legal battles over compounded semaglutide and tirzepatide — the FDA has argued that compounded versions of these drugs are essentially copies of the commercially available branded products, while compounding pharmacies have argued they are permitted because of demonstrated drug shortages.

The Bulk Drug Substance List

For 503B facilities, the FDA maintains a list of bulk drug substances that can be used in compounding. Substances on this list have been evaluated and deemed appropriate for use in outsourcing facility compounding. Substances not on the list — or those on the FDA's "difficult to compound" list — may face restrictions.

The FDA periodically reviews and updates these lists, and its decisions can have immediate market effects. When the FDA adds a substance to the "difficult to compound" list or removes it from the approved bulk substances list, compounding pharmacies may be forced to stop producing that peptide — potentially disrupting access for thousands of patients.

State-Level Regulation

While federal law sets the baseline, state regulation adds another layer. State boards of pharmacy license and inspect compounding pharmacies within their jurisdictions. State medical boards regulate prescribers. And some states have enacted specific laws related to compounding, telehealth prescribing, or peptide access that go beyond federal requirements.

This state-level patchwork means that peptide access can vary significantly by geography. A peptide compounded and prescribed legally in one state may face restrictions in another due to differences in state pharmacy law or board policy. Patients who use telehealth for peptide therapy across state lines must ensure that both the prescriber and the pharmacy are properly licensed in their state.

Where Regulation Is Heading

Several trends are shaping the future of peptide regulation:

• Increased FDA attention to compounding. As the peptide therapy market grows, the FDA has increased its focus on compounding oversight. Expect continued scrutiny of 503B facilities and ongoing challenges to compounded versions of commercially available drugs.
• Semaglutide and tirzepatide as a regulatory flashpoint. The legal battles over compounded GLP-1 drugs are establishing precedents that will affect compounding access for all peptides. Court decisions and FDA policy changes in this area will have ripple effects across the industry.
• Congressional interest. Peptide access has attracted congressional attention from both sides of the political aisle. Legislation has been proposed to both restrict and protect compounding access, and the outcome of these legislative efforts will shape the regulatory landscape for years.
• Patient advocacy. As more patients rely on compounded peptides, advocacy organizations have emerged to protect access. These groups engage in lobbying, legal challenges, and public education campaigns.
• Global regulatory divergence. Other countries regulate peptides differently, creating a global patchwork. Some peptides available by prescription in Australia or parts of Europe are not available through any legal pathway in the US, and vice versa.

This article is for informational purposes only and does not constitute legal or medical advice. Regulatory information can change rapidly — verify current status through official sources.

In the final article of this series, we step back to take a historical perspective — tracing the 125-year arc from the discovery of the first peptide hormone to the modern era of semaglutide and beyond.